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Background: Guanylate binding protein-1 (GBP-1) is a large GTPase which is actively secreted by endothelial cells.
It is a marker and intracellular inhibitor of endothelial cell proliferation, migration, and invasion. We previously
demonstrated that stable expression of GBP-1 in murine endothelial progenitor cells (EPC) induces their premature
differentiation and decreases their migration capacity in vitro and in vivo. The goal of the present study was to
assess the antiangiogenic capacity of EPC expressing GBP-1 (GBP-1-EPC) and their impact on blood vessel formation
in an axially vascularized 3-D bioartificial construct in vivo.
Results: Functional in vitro testing demonstrated a significant increase in VEGF secretion by GBP-1-EPC after
induction of cell differentiation. Undifferentiated GBP-1-EPC, however, did not secrete increased levels of VEGF
compared to undifferentiated control EPC expressing an empty vector (EV-EPC). In our In vivo experiments, we
generated axially vascularized tissue-engineered 3-D constructs. The new vascular network arises from an
arterio-venous loop (AVL) embedded in a fibrin matrix inside a separation chamber. Total surface area of the
construct as calculated from cross sections was larger after transplantation of GBP-1-EPC compared to control EV-
EPC. This indicated reduced formation of fibrovascular tissue and less resorption of fibrin matrix compared to
constructs containing EV-EPC. Most notably, the ratio of blood vessel surface area over total construct surface area
in construct cross sections was significantly reduced in the presence of GBP-1-EPC. This indicates a significant
reduction of blood vessel density and thereby inhibition of blood vessel formation from the AVL constructs caused
by GBP-1. In addition, GBP-1 expressed from EPC significantly reduced cell apoptosis compared to GBP-1-negative
controls.
Conclusion: Transgenic EPC expressing the proinflammatory antiangiogenic GTPase GBP-1 can reduce blood vessel
density and inhibit apoptosis in a developing bioartificial vascular network and may become a new powerful tool
to manipulate angiogenetic processes in tissue engineering and other pathological conditions such as tumour
angiogenesis.
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The role of endothelial progenitor cells (EPC) in the for-
mation of new blood vessels has been the focus of intense
research and debate over the past years but the involved
mechanisms remain unclear. In pathologic conditions in-
volving tissue ischemia such as myocardial infarction, limb
ischemia, and tumor angiogenesis [1,2], EPC are chemo-
tactically recruited from bone marrow and the peripheral
blood to the site of injury where they differentiate into ma-
ture endothelial cells. These cells may contribute directly
to de novo microvascular blood vessel formation, a process
termed vasculogenesis [1]. Alternatively, they may act
through a more paracrine manner by secretion of proan-
giogenic growth factors such as VEGF rather than inte-
grate directly into newly formed blood vessels, [3].
At the same time, EPC recruitment and proangiogenic
potential may be adversely influenced by an unfavour-
able microenvironment [4]. It has been previously shown
that chronic inflammation and increased levels of proin-
flammatory cytokines induce the secretion of the large
GTPase Guanylate binding Protein-1 (GBP-1) from
endothelial cells. GBP-1 mediates the potent antiangio-
genic effects of the cytokines TNF-α, IFN-γ and IL-1
in vitro and in vivo [5-8].
To investigate the function of GBP-1 in EPC, we pre-
viously established EPC stably expressing GBP-1 (GBP-1-
EPC) and performed extensive functional in vitro
characterization [9]. Premature differentiation as indicated
by upregulation of vWF and VEGFR-2 was observed in
these transgenic cells compared to control cells carrying an
empty vector only. Furthermore, GBP-1 inhibited the pro-
liferation and migration of EPC in vitro. EPC were then
suspended in a fibrin matrix which was placed in a sepa-
ration chamber containing a microsurgically created AV
vessel loop. The AV loop provides a well established and
highly standardized in vivo model of predictable blood ves-
sel formation generated from an axial vascular axis [10,11].
After even distribution of EPC in the fibrin matrix, expres-
sion of GBP-1 prevented cell migration towards the central
vessels of the construct compared to control cells [9].
Based on these findings, the aim of the current study
was to perform further functional testing related to
angiogenic capacity of GBP-1-EPC in vitro and to inves-
tigate the impact of the anti-angiogenic cytokine GBP-1
on the morphometry of the tissue-engineered construct
as well as its blood vessels in vivo.
Results
VEGF secretion in vitro
We quantified the ability of EV EPC and GBP-1 EPC to se-
crete VEGF under incubation with basal medium as well as
differentiation medium. No significant difference was noticed
when basal medium was used (1.25 ± 0.01 pg/ml/105 cells
vs. 1.33 ± 0.01 pg/ml/105 cells, respectively, Figure 1).However, differentiation medium induced a significant
stimulation of VEGF secretion in EV EPC and even more so
in GBP-1 EPC (p<0.05). VEGF secretion from GBP-1 EPC
was 86 ± 2 pg/ml/105 cells, while secretion from EV EPC
was significantly lower, reaching 39 ± 3 pg/ml/105 cells
(p<0.05, Figure 1).
Surgery and animals
All animals tolerated the surgical procedure well without
any major complications such as thrombosis of the vascu-
lar axis, extrusion of the chambers, infections or hemato-
mas. Patency of the AVLs was assessed during the
explantation after Microfil perfusion and during histo-
logical examination, revealing no signs of thrombosis.
Macroscopic appearance
After explantation, vascularization of matrices was vi-
sible by yellow appearing filling of vessels with Microfil
solution.
Macroscopic inspection revealed relatively stable fibrin
clots at day 14. There was a slight macroscopic difference
between the groups, with the AV loops containing EV EPC
showing slightly more signs of clot degradation compared
to EPC GBP-1 clots. There was some vascularization of
matrices detectable. All AV loops were macroscopically pa-
tent upon explantation (Data not shown).
Micro-CT
The vascular network could be visualized by micro-CT
of the specimens (n = 4 per group; Figure 2). In both
groups, neovascularisation was evident arising from the
main vascular axis. There was a difference which was
particularly evident in the area of the contralateral inter-
positional vein graft, where new blood vessels appeared
more numerous and displayed more advanced growth
away from the AV loop in the EV EPC group
(Figure 2A). In contrast, GBP1 expression reduced vessel
ingrowth away from the AV loop (Figure 2A).
Histology
Morphometric analysis was based on histological cross
sections of explanted constructs. We previously demon-
strated that vessels perfused with Microlfil could be
identified histologically by black-appearing filling of the
lumina [9]. Moreover, the fibrovascular tissue evolving
from the two central vessels, artery and vein, could be
clearly detected and its margins were easily discernible
from the adjacent fibrin matrix. No infections were
noticed macroscopically and histologically as indicated
by the absence of inflammatory cells. Apart from the
quantitative differences in blood vessel number, con-
struct surface area and blood vessel density there were
no differences between the two study groups (Data not
shown).
Figure 1 VEGF secretion from cultured EPC in vitro incubated with basal medium (BM) or differentiation medium (DM). Results are
presented on a logarithmic scale. There is a significant increase in VEGF production upon differentiation in both EV-EPC and GBP-1-EPC. There is
no significant difference between EV-EPC and GBP-1-EPC when basal medium is used. After incubation with differentiation medium, however,
GBP-1-EPC secrete significantly higher levels of VEGF into the supernatant medium compared to EV-EPC. (p<0.05).
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There was no significant difference in the numbers of blood
vessels per region of interest (ROI) between the two groups
(6.25 ± 2.56 blood vessels/ROI in EV EPC vs. 4.66 ± 1.46
blood vessels/ROI in GBP-1 EPC) (Figure 2B).
The total construct surface area measurement of cross
sections from EV-EPC containing constructs was 52.25 ±
23.5 mm2, while there was an average of 73.25 ± 17.71
mm2 surface area for GBP-1 EPC. There was no statisti-
cally significant difference (p>0.05) (Figure 2C).
The ratio of total blood vessel surface area to total
construct surface area as an indicator for blood vessel
density within the construct revealed a significant reduc-
tion by more than three-fold of the percentage of vascu-
larised area in the GBP-1-EPC group compared to
control EV EPC (0.13 ± 0.06% vs 0.04 ± 0.01% vascu-
larised total surface area per total construct surface area,
n = 4 constructs per group; p<0.05, Figure 2D).
Immunohistochemistry and apoptosis
Caspase-3 staining revealed a significant difference in apop-
tosis rate, with 71 ± 28 Caspase 3-positive cells/ROI in EV
EPC constructs vs. 48 ± 23 Caspase-3-positive cells/ROI in
GBP-1 EPC, indicating a significant reduction in cell apop-
tosis in the AV loop in the presence of GBP-1 expression
from transplanted EPC (p<0.05, Figure 3). Caspase-3 posi-
tive cells can be identified by their red staining.
Fluorescence microscopy
Fluorescence microscopy was carried out for constructs
containing either GBP-1 EPC (Figure 4A, B) or EV EPC(Figure 4C, D). Two different magnifications show over-
view (Figure 4A, C or detail photograps (Figure 4B, D) of
representative areas for both study groups. BS-1 lectin
(green fluorescence) was used to label functional blood
vessels. There was an increased number of DiI-expressing
EV EPC (red fluorescence) in the close vicinity of small
blood vessels (Figure 4D) while GBP-1 expressing EPC
were not closely co-localized with blood vessels
(Figure 4B). Equal distribution was shown for cells con-
taining nuclei by DAPI staining (Data not shown).
Discussion
The term “therapeutic vasculogenesis” was coined by
Isner and Asahara [12] to imply that de novo blood ves-
sel formation in adulthood can occur from differentiat-
ing endothelial progenitor cells derived from the bone
marrow and peripheral blood. In the following years, tre-
mendous efforts have been made in a multitude of ex-
perimental and clinical studies using EPC to stimulate
blood vessel formation in ischemic conditions such as
myocardial infarction and limb ischemia [13]. Even
though a number of clinical trials have demonstrated en-
couraging results and therapeutic effects of EPC in
patients with myocardial ischemia [14] and peripheral
vascular disease [15], conflicting studies have raised
questions regarding mechanisms of action and efficacy
of EPC in different pathological settings [16]. Indeed, it
has been shown that EPC numbers and function are
decreased in conditions such as diabetes [17] and
rheumatoid autoimmune disorders [18,19]. Serum levels
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Figure 2 A. Micro CT scans of explanted constructs. At 14 days, micro-computed tomography demonstrated newly formed vessels, radiating
from the arteriovenous loop in both groups. There appeared to be less neovessel formation in the GBP-1-EPC group (left) compared to EV-EPC
(right). One particular source of neovessel formation appears to be the interposed graft from the contralateral femoral vein (arrow). Scale Bar =
3 mm. B. Morphometric Analysis of Number of Blood Vessels. At the time of explantation after 2 weeks, there was no significant difference in the
average number of blood vessels per region of interest. N= 4 animals per group. 2 independent cross section analyses per animal and
construct were performed, i.e. 8 values per group were obtained and evaluated including statistical analysis. C. Morphometric Analysis
of Construct Cross Section Size. At the time of explantation 2 weeks after surgery, GBP-1-EPC containing constructs had a larger cross section
compared to EV- containing EPC, however, this difference was not statistically significant. N= 4 animals per group. 2 independent cross
section analyses per animal and construct were performed, i.e. 8 values per group were obtained and evaluated including statistical
analysis. D. Morphometric Analysis of Blood Vessel Density in Construct Cross Sections. Presented as the ratio of blood vessel surface area over
total construct surface area, a significant reduction of the percentage of vascularized area in the GBP-1-EPC group compared to control EV EPC is
noted. * p<0.05 vs. EV-EPC. N= 4 animals per group. 2 independent cross section analyses per animal and construct were performed, i.e.
8 values per group were obtained and evaluated including statistical analysis.
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arthritis and other autoimmune inflammatory disorders
[19]. These cytokines exhibit an inhibitory effect on pro-
liferation and migration of endothelial cells through the
GTPase GBP-1 [5-8]. In this context, GBP-1 has been
identified as a potent anti-angiogenic mediator in colo-
rectal carcinoma, where a positive correlation was
found between a high GBP-1 expression from tumor
endothelial cells and reduced angiogenesis within the
tumor [20].
We recently investigated potential effects of GBP-1 on
endothelial progenitor cell function [9] and aimed to iden-
tify antiangiogenic mechanisms that could explain EPC
dysfunction in the inflammatory state [21] and associated
cardiovascular disease [22]. The well characterized murineEPC line T17b was stably transfected with GBP-1. Com-
pared to T17b expressing empty vector as a control (EV
EPC), GBP-1 was sufficient to induce premature differen-
tiation in EPC, while proliferation and migration were
inhibited in vitro [9]. In the AVL model, GBP-1 EPC mi-
gration towards the central vessels was significantly
reduced compared to EV EPC controls [9].
In the present study, we further characterized the in-
fluence of GBP-1 on EPC and construct morphometry
in a developing three dimensional vascular network in
the AVL model. Further functional in vitro testing
revealed increased VEGF secretion from GBP-1 EPC
compared to EV EPC under differentiation, while there
was no difference in VEGF secretion under incubation
with basal medium. Hence, VEGF secretion is associated
EV-EPC
GBP-1-EPC
Figure 3 Visualisation and Quantification of Apoptosis in Constructs by Caspase-3 IHC. There was a significant reduction in the number of
apoptotic cells seen in constructs containing GBP-1 EPC compared to EV-EPC. * P< 0.05 vs. EV EPC. N= 4 animals per group. 2 independent
cross section analyses per animal and construct were performed, i.e. 8 values per group were obtained and evaluated including
statistical analysis. Scale Bar = 50 μm.
Figure 4 Identification and Localisation of EPC. Fluorescence staining for blood vessels in green with BS-1 lectin and transplanted DiI-labelled
EPC in red. The number of GBP-1 EPC that can be found near the capillaries is much smaller (A) compared to numerous EV-EPC found in the
near vicinity of newly formed blood vessels (B). Scale Bar = 100 μm (A , C); Scale Bar = 25 μm (B, D).
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differentiate in situ within the construct. This is a fur-
ther corroboration of our previous finding that prema-
ture differentiation in vivo prevented GBP1 EPC
migration within the AVL construct towards the central
blood vessels [9].
In vivo, Micro CT scans showed neo-vessel formation
arising from the main vascular axis in both groups. This
finding was confirmed by morphometric analysis of con-
ventional histological cross sections. There was visible
blood vessel ingrowth towards the center of the con-
struct from the interposed contralateral venous graft in
the EV EPC group which was not present in the GBP-1
EPC group. This may indicate that GBP-1 may not only
be an intracellular inhibitor of angiogenesis in the endo-
thelial cells itself, but prevent vascular ingrowth towards
regions with high levels of GBP-1 expression. Even
though we noticed increased VEGF expression in GBP-
1-EPC after differentiation in vitro by ELISA, the pres-
ence of GBP-1 in vivo may locally interfere with the
proangiogenic stimulus associated with the expression of
VEGF in our in vivo model. It may be an unexpected
finding that the transplanted GBP-1-EPC secrete sub-
stantial amounts of VEGF in vitro, yet fail to stimulate
angiogenesis efficiently in vivo. We previously demon-
strated, however [9], that concomitant GBP-1 exression
inhibits EPC migration towards the site of active angio-
genesis in our AVL microsurgical model. This may pre-
clude EPC participation in neoangiogenesis since GBP-1
are unable to home to the region where they could ex-
hibit an effect on the vascularisation process. Indeed,
EPC may in this case secrete increased VEGF levels, un-
able to migrate to the site where they could exhibit a
biological effect towards angiogenesis. On the other
hand, we demonstrated that EPC lacking GBP-1 were
often located in the close vicinity of newly formed blood
vessels, supporting the assumption that they secrete
proangiogenic growth factors in vivo, supporting neovas-
cularisation through a paracrine fashion.
Our experimental results are supported by clinical
findings in colorectal cancer patients where increased
GBP-1 expression from endothelial cells was associated
with a reduction in angiogenesis [20].
We measured a 29% reduction in cross section size of
AVL constructs containing EV EPC compared to GBP-1
EPC constructs. Our group previously demonstrated re-
duction of cross section size of the AVL constructs when
recombinant growth factors VEGF and bFGF were sus-
pended within the fibrin matrix, leading to increased
angiogenesis and fibrovascular tissue formation [23].
These findings indicate that cross section size of the con-
struct can be used as an indicator for shrinkage due to
increased fibrovascular tissue inside formation. This sup-
ports the hypothesis that GBP-1 prevented blood vesselformation and hence concomitant degradation of the fi-
brin construct. Previous work from our group by Arkudas
et al. [23] demonstrates that fibrin loaded with recombi-
nant VEGF does effectively support blood vessel growth in
a dose dependent manner. In this setting, however, VEGF
is likely homogenously distributed within the fibrin gel,
which does not appear top be the case with the trans-
planted EPC in our study. The presence of GBP-1 reduces
EPC migration capacity, and areas where VEGF expres-
sion is particulary high do exert a negative chemotactic ef-
fect on GBP-1 expressing cells, i.e. GBP-1-EPC cannot
locate to the vicinity of intense growth of new blood ves-
sels. To further elucidate the impact of GBP-1 on the
angiogenic stimulus in our AVL model, we assessed the
ratio of total blood vessel surface area to total construct
surface area in complete representative construct cross
sections. Of note, we found a significant reduction in the
percentage of blood vessel surface area in relation to the
total construct, indicating a reduced vascular density at-
tributable to GBP-1 expression from EPC. Unfortunately,
it is difficult to pinpoint the exact mechanisms by which
EPC exhibit their effects in this study. Based on the distri-
bution pattern of fluorescently labelled EV-EPC, it appears
that they exerted their proangiogenic effect mostly in a
paracrine fashion rather than being directly integrated into
newly formed blood vessels. Overexpression of GBP-1 in
EPC has been shown to reduce their migratory capacity as
well as their potential for capillary formation [5]. We also
previously confirmed that GBP-1 inhibited vessel-directed
migration of EPC at the tissue level using the rat arterio-
venous loop model [9]. Hence, we stipulate that several
mechanisms contribute to reduced blood vessel formation
of GBP-1 EPC. On the one hand, it is cell-inherent due to
the antiangiogenic effect of GBP-1. On the other hand,
GBP-1 EPC appear to be less capable to localize to areas
of intense angiogenesis where they are most needed to
exert their function.
It is also known that GBP-1 has an anti-apoptotic ef-
fect on endothelial cells. The rate of apoptosis in our
construct, as detected by Caspase-3 staining, was signifi-
cantly reduced in the GBP-1 EPC - Group. This may in-
dicate an antiapoptotic effect induced by GBP-1. This
hypothesis is supported by findings from Pammer et al.
where human umbilical vein endothelial cells (HUVEC)
were protected from apoptosis upon transfection with
an expression vector for GBP-1 [24]. They further attrib-
uted the antiangiogenic effect to the fact that GBP-1
induces senescence in endothelial cells rather than
apoptosis.
Conclusion
Taken together, this is the first study demonstrating the
potential of the antiangiogenic proinflammatory large
GTPase GBP-1 to alter EPC behaviour, reduce apoptosis
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developing vascular network. These results may open a
new option towards antiangiogenic treatment strategies
to inhibit undesired angiogenesis and target inhibition to
defined regions of angiogenetic activity in cancer and
other disease conditions.
Methods
Cell culture and stable transfection
The endothelial progenitor cell line T17b has been pre-
viously isolated from mouse embryos and was cultured
as previously described [25]. Briefly, cells were main-
tained in DMEM Glutamax (Invitrogen, Carlsbad, CA,
USA) containing 20% fetal bovine serum, 100 U/ml
Penicillin, 100 μg/ml Streptomycin, 0.1mM β-Mercap-
toethanol, 1 mM non-essential amino acids and 2 mM
HEPES buffer pH 7.5 (all purchased from Invitrogen).
As opposed to this basal medium (BM), cell differen-
tiation was induced by incubation with differentiation
medium (DM) where BM was supplemented with 0.5 mM
dibutyryl cyclic AMP (cAMP) (Sigma Aldrich Chemie,
Schnelldorf, Germany) and 1 μM retinoic acid (RA)
(Sigma Aldrich Chemie) for 3 consecutive days. Cells were
maintained in T-75 culture flasks (Nunc, Wiesbaden,
Germany) coated for 2 hours with 0.1% bovine skin gel-
atine, type B (Sigma Aldrich, Taufkirchen, Germany) in
phosphate-buffered saline (PBS) (Biochrom AG, Berlin,
Germany). The cells were subcultured using 1 x 0.5 g/L
trypsin and 0.2 g/L ethylene-diamine-tetra-acetic acid in
HBSS (trypsin/EDTA) (PAA, Pasching, Austria) and pas-
saged in a 1:8 ratio. Cells were counted using the CASYcell
counting system (Schärfe System, Model DT, Reutlingen,
Germany). Cells were tested for mycoplasma infection on
a regular basis using MycoAlert (Cambrex, Charles City,
USA). All results were negative.
EPC expressing the transgene GBP-1 were generated
through clonal selection as previously described [9].
Briefly, 1 x 105 cells per well were seeded in precoated
6-well plates. After 24 hours, transfection was carried
out using the Effectene transfection reagent (Quiagen,
Hilden, Germany) with 2 μg Plasmid DNA. pMCV-2.2
and pMCV-2.2-Flag-GBP-1 plasmids. A G418 resistance
gene was employed in both plasmids and selection was
carried out for 10 days with 500 μg/ml G418 (PAA) fol-
lowed by successful selection of an EPC clone expressing
GBP-1 stably and at biologically siginifcant levels [9].
To quantify VEGF secretion from EPC expressing GBP-
1 and control EPC, cells were seeded at 5 x 105 cells and
incubated with either differentiation medium or basal
medium for 4 subsequent days where medium was chan-
ged on a daily basis. In either case, T17b EPC culture
supernatant was collected at day 4 24 hrs after the last
medium change and VEGF secretion was quantified using
a VEGF ELISA kit (R&D Systems, Minneapolis, MN,USA) according to the manufacturer’s instructions.
Experiments were carried out in triplicates and repeated
twice.
Labeling of EPC
EPC were labelled with the fluorescent carbocyanine DiI
dye (Molecular Probes) prior to transplantation as pre-
viously described [15] in order to facilitate tracking and
localisation. In brief, before cellular transplantation,
EPCs in suspension were washed with PBS and incu-
bated with DiI at a concentration of 2.5 μg/ml PBS for
5 minutes at 37°C and 15 minutes at 4°C. After two
washing steps in PBS, the cells were resuspended in
DMEM Glutamax medium.
Experimental design in vivo
Two experimental groups employing 4 animals per
group were investigated. Both groups received EPC sus-
pended in the fibrin matrix where the AVL was embed-
ded. One group of animals received GBP-1-EPC, the
other group received EV-EPC as a control. At day 14
after surgery experiments were terminated and con-
structs explanted for further analysis.
Animals
Male Lewis rats (Charles River Laboratories, Sulzfeld,
Germany) were used and German regulations for the
care and use of laboratory animals were observed
throughout the entire study.
All experiments were approved by the animal care
committee of the University of Erlangen and the Go-
vernment of Mittelfranken, Germany (Approved Proto-
col 54–2532.1-28/09).
Animals were housed in the veterinary care facility of
the University of Erlangen Medical Center and submit-
ted to a 12-hour dark–light cycle with free access to ro-
dent standard diet (Altromin, Hamburg, Germany) and
tap water.
Surgical procedures
The animals were anesthetized by general anesthesia with
Isoflurane (Baxter, Unterschleißheim, Germany). The
AVL was created as described previously [26]. Briefly,
through longitudinal skin incisions both femoral vessels
were exposed and dissected from the groin to the knee.
A 20 mm vein graft was harvested from the right femoral
vein. Interposing this graft in retrograde fashion an ar-
teriovenous loop was created between the left femoral ar-
tery and vein by end-to-end anastomosis using 11–0
sutures (Ethicon, Norderstedt, Germany). Chambers con-
taining 5x106 EV-EPC or GBP-1-EPC suspended in
500 μl of a clinically approved fibrin gel (Tissucol,
Baxter, Unterschleißheim, Germany) with a fibrinogen
concentration of 10 mg/ml, a thrombin concentration of
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to delay fibrinolysis were implanted. In detail, the cham-
ber was filled with 250 μl fibrin gel – EPC suspension,
and the AV loop was passed around the four plastic
sticks. Then, the chamber was filled with the second half
of the fibrin-EPC suspension to a total volume of 500 μl,
the lid was closed, and the chamber was fixed in the groin
using Prolene 3–0 (Ethicon, Norderstedt, Germany)
sutures. For analgesia buprenorphin (0.3 mg/kg rat weight,
Temgesic, Essex Chemie AG, Luzern, Switzerland) was
administered postoperatively. Also all animals received
0.2 ml benzylpenicillin-benzathin (Tardomycel, Bayer, Le-
verkusen, Germany), and heparine (80 I.U./kg Liquemin,
Ratiopharm, Germany). 30 minutes before animals were
sacrificed, they received an intravenous injection of of 500
μg Bandeirea Simplicifolia Lectin (BS-1 l) conjugated with
FITC (Vector Laboratories). 4 constructs per group were
examined.
Explantation procedure and microfil® injection
At 2 weeks after the initial AV loop implantation rats
were anesthetized by general anesthesia with Isoflurane
and the aorta and the inferior vena cava were exposed
through a median incision from the xiphoid process to
the pubic symphysis. After cannulation of the aorta the
vena cava was cut and the vascular system of the rat was
flushed with 200 ml heparinized Ringer solution (100 I.
U./ml). The caudal vascular system was then rinsed with
20 ml yellow MicrofilW (MV-122) containing 5% of MV
Curing Agent (both from Flowtech, Mass., USA). Finally
the rats were cooled at 4°C for 24h and the constructs
were harvested in toto and fixed in 3.5% formalin
solution.
Micro-computed tomography (micro-CT)
One specimen per group was studied using mirco-CT
for qualitative evaluation. Therefore the tube containing
the explanted construct was placed on the table of a
Micro-CT scanner (FORBILD, High Resolution Micro-
CT, Erlangen, Germany). Scanning parameters were as
follows: tube voltage 40 kV, 250 μA, 15 μm voxel size,
tube-detector-distance: 250 mm.
Histological and statistical analysis
4 constructs per group were explanted in toto with the
surrounding tissue. After fixation in 3.5% formalin solu-
tion, constructs were dehydrated in graded ethanol and
embedded in paraffin. 3 μm cross sections were obtained
using a Leica microtome (Leica Microsystems, Bensheim,
Germany) where two standardized planes were defined
(1 mm proximal and 1 mm distal of the central plane)
rectangular to the longitudinal axis of the AV loop.
Hematoxylin eosin (HE) staining was performed
according to standard protocols. Immuno-histochemicalstaining was performed using the fluorescent Bandeiraea
Simplicifolia agglutinin (BS-1) and Lectin. Fluorescence
microscopy was carried out to detect EPC labelled with
Di-I in vitro prior to implantation and ingrowing blood
vessels decorated with BS-1 lectin which was intraven-
ously injected immediately prior to sacrification of the
animals.
The images were evaluated by an independent and
blinded observer. All images of H&E stained cross sec-
tions were generated with a Leica microscope and digital
camera using 25 x magnification.
Immunohistochemistry
Lectin: The lectin Bandeiraea Simplicifolia agglutinin
(BS-1) was used for immunohistochemical detection of
rat endothelial cells [4]. Paraffinated sections were sub-
mitted to a xylol/ethanol sequence, rinsed in PBS fol-
lowed by blocking of endogenous peroxidise activity in
H2O2 for 10 minutes. Blocking was completed by incu-
bation with avidin and biotin 15 minutes each (Vector
Laboratories, California) as well as 5% goat serum for 1
hour. Overnight incubation was performed with Biotiny-
lated lectin (BS-1, Sigma) in a 1:100 dilution in PBS
overnight at 4°C. Slides were rinsed in PBS between in-
cubation steps. Detection was achieved by incubation
with Streptavidin AB Complex/HRP (Dako GmbH, Ger-
many) for 30 minutes followed by development with
DAB + Chromogen (Dako GmbH). Cardiac muscle sec-
tions were used as positive controls, while absence of
lectin served as negative control.
Caspase-3: Cleaved Caspase-3 staining was used for
immunohistochemical detection of apoptosis. After
deparaffination antigen retrieval was performed by boil-
ing of sections in TRS-buffer pH 6 (Dako GmbH) for
2,5 minutes using a pressure cooker und followed by
blocking of endogenous peroxidase activity in H2O2 for
10 minutes. Blocking was completed by incubation with
avidin and biotin 20 minutes each (Vector Laboratories,
California) as well as 1% bovine serum albumin (BSA)
for 1 hour at room temperature. Slides were rinsed in
PBS between incubation steps. Detection was achieved
by incubation with primary polyclonal rabbit antibody
anti-cleaved Caspase-3 (DCS-diagnostics, Hamburg,
Germany) at a dilution of 1:100 for 40 min at 37°C. A
secondary goat anti rabbit antibody (Vector laboratories,
Burlingame, USA) at a dilution of 1:200 was subse-
quently used for 30 min incubation at room termpera-
ture. After washing with TRIS buffer, ABC solution
(Vector Laboratories, Eching, Germany) was used ap-
plied for 30 min followed by Tyarmid enhancement
using the NEN kit (Perkin Elmer, Rodgau, Germany) for
15 min at 1:50 dilution. Thereafter, ABC solution (Vec-
tor laboratories) was applied again for 15 min. Followed
by AEC for 2 min and Hemalaun staining.
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Morphometric analysis was performed by blinded obser-
vers. In brief, total cross section surface area of the con-
struct was quantified for both groups, GBP-1 EPC and
control EPC, according to the method previously
described by Arkudas et al. [27]. In brief, three-mm
cross sections were obtained from 2 standardized planes.
Both planes were oriented rectangular to the longitu-
dinal axis of the AV loop. One plain was located 1 mm
proximal, the other 1 mm distal to the transverse mid-
line. Hence, 2 cross section analyses per animal and con-
struct were performed, resulting in a total of 8 cross
sections of the entire construct per each of the two ex-
perimental groups. The mean value was calculated for
each group and each parameter. To determine the num-
ber of blood vessels per cross section, blood vessel distri-
bution, and total blood vessel surface area all H&E
stained cross sections were split into 14 sectors, 6 at the
periphery, 4 at the central part of the section and each 2
at the artery and vein [27]. Afterwards, the images of
each sector (200x magnification) were rendered bimodal
using a standardized threshold (WinQ, Leica Microsys-
tems, Bensheim, Germany) followed by the calculation
of the above mentioned parameters.
Fluorescence microscopy
Images were generated with a Leica microscope using
200 x magnification. Appropriate filter systems for de-
tection of the double fluorescence labelling was used
(red – Di-I; green – BS-1 lectin).
Statistical analysis
Results are presented as mean ± standard deviation.
Statistical analysis was carried out GraphPad Prism soft-
ware (GraphPad Software, San Diego, USA). Two-tailed
unpaired student’s t-test was applied for statistical analysis.
A p value <0.05 was determined statistically significant.
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